Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Enhancement of Therapeutic Dna Vaccine Potency by Melatonin Through Inhibiting Vegf Expression and Induction of Antitumor Immunity Mediated by Cd8+ T Cells Publisher Pubmed



Baghban Rahimi S1 ; Mohebbi A1, 2 ; Vakilzadeh G3, 4 ; Biglari P2 ; Razeghi Jahromi S5 ; Mohebi SR6 ; Shirian S7 ; Gorji A4, 8 ; Ghaemi A2, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
  2. 2. Department of Virology, Pasteur Institute of Iran, P.O. Box: 1316943551, Tehran, Iran
  3. 3. Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
  5. 5. Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Pathology, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran
  8. 8. Department of Neurosurgery and Neurology, Westfalische Wilhelms-Universitat Munster, Robert-Koch-Strasse 27a, Munster, 48149, Germany
  9. 9. Department of Microbiology, Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Source: Archives of Virology Published:2018


Abstract

To be effective, therapeutic cancer vaccines should stimulate both an effective cell-mediated and a robust cytotoxic CD8+ T-cell response against human papillomavirus (HPV)-infected cells to treat the pre-existing tumors and prevent potential future tumors. In this study, the therapeutic experiments were designed in order to evaluate antitumor effect against the syngeneic TC-1 tumor model. The anti-tumor efficacy of a HPV-16 E7 DNA vaccine adjuvanted with melatonin (MLT) was evaluated in a C57BL/6 mouse tumor model by measuring tumor growth post vaccination and the survival rate of tumor-bearing mice, analyzing the specific lymphocyte proliferation responses in control and vaccinated mice by MTT assay. The E7-specific cytotoxic T cells (CTL) were analyzed by lymphocyte proliferation and lactate dehydrogenates (LDH) release assays. IFN-γ, IL-4 and TNF-α secretion in splenocyte cultures as well as vascular endothelial growth factor (VEGF) and IL-10 in the tumor microenvironment were assayed by ELISA. Our results demonstrated that subcutaneous administration of C57BL/6 mice with a DNA vaccine adjuvanted with MLT dose-dependently and significantly induced strong HPV16 E7-specific CD8+ cytotoxicity and IFN-γ and TNF-α responses capable of reducing HPV-16 E7-expressing tumor volume. A significantly higher level of E7-specific T-cell proliferation was also found in the adjuvanted vaccine group. Furthermore, tumor growth was significantly inhibited when the DNA vaccine was combined with MLT and the survival time of TC-1 tumor bearing mice was also significantly prolonged. In vivo studies further demonstrated that MLT decreased the accumulation of IL-10 and VEGF in the tumor microenvironment of vaccinated mice. These data indicate that melatonin as an adjuvant augmented the cancer vaccine efficiency against HPV-associated tumors in a dose dependent manner. © 2017, Springer-Verlag GmbH Austria, part of Springer Nature.
Other Related Docs
12. Vaccines, Adjuvants, and Delivery Systems, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
16. Vaccines, Adjuvants, and Delivery Systems, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)